HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[ASSESSMENT OF INDICATORS FOR INTERFERON SYSTEM IN PATIENTS WITH COMMON FORMS OF PULMONARY TUBERCULOSIS RECEIVING COMPLEX THERAPY WITH CYCLOFERON].

Abstract
We have evaluated the efficacy of cycloferon inclusion in the complex therapy of newly diagnosed patients with common forms of pulmonary tuberculosis, based on monitoring of the number of monocytes with receptors to interferon-gamma (flow cytometry) and the concentration of interferon-gamma in the serum (ELISA). For this purpose, a group of 36 patients (18 patients received standard chemotherapy, and 18 additionally received 600 mg cycloferon tablets 3 times per week) was examined for 3 months. Control group consisted of 18 apparently healthy patients. The study did not include patients with multiple or extensively drug-resistant M. tuberculosis strains. The analysis of results showed a statistically significant positive dynamics of the level of monocyte receptors to interferon-gamma in patients receiving cycloferon as manifested by an increase in their number in the first 2 months of therapy (period of clinical manifestations of the disease), followed by a decrease in the 3rd months of treatment, which corresponds to clinical improvement, in contrast to patients treated with standard chemotherapy alone.
AuthorsA M Budritskii, N S Pravada
JournalEksperimental'naia i klinicheskaia farmakologiia (Eksp Klin Farmakol) Vol. 78 Issue 6 Pg. 15-8 ( 2015) ISSN: 0869-2092 [Print] Russia (Federation)
PMID26292509 (Publication Type: Evaluation Study, Journal Article)
Chemical References
  • Acridines
  • Interferon Inducers
  • Receptors, Interferon
  • interferon gamma receptor
  • 10-carboxymethyl-9-acridanone
Topics
  • Acridines (administration & dosage)
  • Adolescent
  • Adult
  • Female
  • Humans
  • Interferon Inducers (administration & dosage)
  • Male
  • Middle Aged
  • Monocytes (metabolism)
  • Receptors, Interferon (blood)
  • Time Factors
  • Tuberculosis, Pulmonary (blood, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: